Rapamycin and Longevity: What the Human Evidence Shows in 2026

Few drugs carry as much promise in aging research as rapamycin. In laboratory animals it is the most consistent lifespan extender we have. In people, it has become one of the most talked-about off-label longevity drugs. A large new study of kidney transplant recipients now adds an important, sobering data point. Here is what the evidence shows, and what it does not.

What rapamycin is and how it works

Rapamycin (sirolimus) is an FDA-approved drug used to prevent organ transplant rejection and for a few other specific conditions. It inhibits mTOR, a central growth and nutrient-sensing hub inside cells. When nutrients are plentiful, mTOR drives growth. When it is dialed down, cells shift toward maintenance and recycling, a process called autophagy.

That biology connects to several hallmarks of aging, including deregulated nutrient sensing, loss of proteostasis and immune aging. Explore the hallmarks on our Science page, and see how rapamycin compares with other approaches on our Therapeutics page.

The animal evidence that started it all

In 2009, the NIA Interventions Testing Program reported that rapamycin fed to genetically diverse mice starting at 600 days of age extended both median and maximum lifespan. Based on age at 90% mortality, lifespan rose by 14% in females and 9% in males, and the effect replicated across three independent test sites (Harrison et al., Nature 2009).

That result made rapamycin a reference point for the whole field. A drug started late in life, in mammals, across both sexes and three sites, made animals live longer. Very few interventions have matched that.

What human studies have shown so far

Human data are much thinner, and they mostly measure function or safety, not lifespan.

Immune function in older adults

In a 2014 randomized trial, older volunteers given the mTOR inhibitor everolimus (RAD001, a close relative of rapamycin) had about a 20% better response to the influenza vaccine. The drug also reduced the share of T cells carrying PD-1, a receptor that dampens T-cell signaling and rises with age (Mannick et al., Sci Transl Med 2014). It was one of the first signs that mTOR inhibition could affect an aging-related process in people.

The PEARL trial in healthy adults

PEARL was a 48-week, double-blind, placebo-controlled trial of low-dose weekly compounded rapamycin in healthy, normally aging adults (Moel et al., Aging 2025). It missed its primary endpoint: visceral fat did not change. Adverse events were similar across groups, which supports short-term safety in this setting. Women taking the higher dose showed improvements in lean tissue mass and self-reported pain, and some well-being measures improved at the lower dose. These are secondary findings that need confirmation.

The new 11-year transplant registry study

In November 2026, researchers published one of the largest real-world looks at long-term human rapamycin exposure (Stewart and Fitzsimmons, GeroScience 2026). Using US national transplant registry data, they compared 4,885 kidney transplant recipients prescribed rapamycin with 6,589 who were not. All were alive with a working graft one year after transplant, and median follow-up was 11 years.

After adjusting for age, BMI, diabetes and 15 other factors, median survival age was 64.6 years with rapamycin and 64.3 years without it. The confidence interval ran from 1.6 years shorter to 2.0 years longer. In short, there was no meaningful survival advantage. Read our full research summary.

How to read the transplant result

This study is important, but it is not the final word.

• The population is different. Transplant recipients live with kidney disease and the burdens of transplant care, which could hide a modest effect on aging biology.

• The use is different. Patients took rapamycin as part of transplant immunosuppression, not as an intermittent, low-dose longevity strategy. The abstract does not report dose or duration.

• The outcome is narrow. Survival is the hardest endpoint, but healthspan also includes immune resilience, muscle, cognition and function.

• It is observational. Even with careful adjustment, unmeasured differences between groups can remain.

What the study does do is temper expectations. If rapamycin had a large effect on human survival, a cohort of this size and follow-up would have had a reasonable chance to see a hint of it. It did not.

Safety and the physician-first principle

Rapamycin suppresses parts of the immune system and has known side effects in its approved uses. Using it for aging is off-label, and no regulator has approved it, or any drug, for the treatment of aging. We do not provide dosing or protocols.

If you are considering rapamycin, the right first step is a conversation with a physician who will review your history, medications and goals, and who can monitor labs if you proceed. The same principle applies to every therapy on our Therapeutics page.

Questions to bring to your physician

If rapamycin has come up in your reading or your social feed, these questions can make a clinic visit more useful.

• What is my current risk profile for infection, diabetes and high cholesterol, and how could an mTOR inhibitor affect it?

• Which of my goals, such as strength, endurance, cognition or immune health, already have stronger evidence behind other approaches?

• If I joined a clinical trial instead, what would that involve?

• Which measurements, such as VO2 max, grip strength, body composition or blood markers, would we track to know whether anything is working?

A good longevity physician will welcome these questions. The goal is not to chase a single molecule but to build a plan that keeps you strong, sharp and independent for as long as possible.

What would settle the question

1. Larger, longer randomized trials of intermittent rapamycin in healthy older adults, with function-based endpoints such as strength, walking speed, immune response and cognition.

2. Validated biomarkers of aging that regulators accept as trial endpoints, the goal of programs such as ARPA-H PROSPR.

3. Independent replication. The XPRIZE Healthspan competition now includes AgelessRx, the sponsor of PEARL, among its ten Milestone 2 awardees, which may generate more controlled human data over the next few years.

Bottom line

Rapamycin remains one of the most compelling drugs in aging biology and one of the least proven in human longevity. The animal evidence is strong. Early human trials suggest effects on immune function and acceptable short-term safety. The largest long-term human dataset shows no survival gain. Living longer only matters if you live youthful, and for now the proven foundations of a youthful healthspan remain fitness, strength, sleep, nutrition and good medical care.

Frequently asked questions

Does rapamycin extend lifespan in humans?

There is no proof that it does. It extends lifespan in mice, but the largest long-term human dataset, an 11-year study of kidney transplant recipients, found no meaningful survival difference.

Is rapamycin FDA-approved for anti-aging?

No. Rapamycin is FDA-approved for preventing transplant rejection and a few other specific uses. Using it for aging is off-label and investigational.

What did the PEARL trial find?

In 48 weeks of low-dose weekly rapamycin in healthy adults, the primary endpoint (visceral fat) did not change. Side effects were similar to placebo, and some secondary measures improved in women on the higher dose.

Should I take rapamycin for longevity?

That is a decision for you and a physician who knows your health history. Rapamycin can suppress the immune system, and human aging benefits are unproven.

Get the evidence without the hype

Join the Longevity Brief for physician-reviewed research updates, or book a consultation with Dr. Farhan Tahir.

This article is for educational purposes only and is not medical advice. It does not create a doctor-patient relationship. Talk with your own physician before starting, stopping or changing any medication.